# Pediatric Formulations of Select Second Line Drugs for Treating Tuberculosis

> **NIH NIH N43** · VIA THERAPEUTICS, LLC · 2021 · $299,995

## Abstract

TO DEVELOP LOW-COST, SHELF-STABLE, PATIENT- ADAPTABLE MINI-TABLETS FOR TREATMENT OF TUBERCULOSIS IN PEDIATRICS

## Key facts

- **NIH application ID:** 10497086
- **Project number:** 75N93021C00042-0-9999-1
- **Recipient organization:** VIA THERAPEUTICS, LLC
- **Principal Investigator:** Ashlee D Brunaugh
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $299,995
- **Award type:** —
- **Project period:** 2021-09-03 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10497086

## Citation

> US National Institutes of Health, RePORTER application 10497086, Pediatric Formulations of Select Second Line Drugs for Treating Tuberculosis (75N93021C00042-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10497086. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*